Aromatase inhibitors for the endocrine adjuvant treatment of breast cancer
- 1 June 2002
- journal article
- editorial
- Published by Elsevier in The Lancet
- Vol. 359 (9324) , 2126-2127
- https://doi.org/10.1016/s0140-6736(02)09111-0
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized TrialJournal of Clinical Oncology, 2001
- Health-Related Quality of Life and Tamoxifen in Breast Cancer Prevention: A Report From the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJournal of Clinical Oncology, 1999
- Tamoxifen in the Treatment of Breast CancerNew England Journal of Medicine, 1998
- Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJNCI Journal of the National Cancer Institute, 1998
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998